Introduction Biosimilars are biologic medications designed to closely replicate the properties
of previously approved biologic disease-modifying anti-rheumatic drugs (bDMARDs). They …

Objective The aim of this study was to assess the efficacy and safety of etanercept (ETA) use
in juvenile idiopathic arthritis (JIA). Methods The 24-month data of patients with JIA on …

Introduction Scientific evidence of the effectiveness of the tumor necrosis factor inhibitor
adalimumab (ADA) in pediatric patients with non-infectious non-anterior uveitis is still …

Purpose The clinical relevance of human leukocyte antigen (HLA) subtypes such as HLA-
B51 on Behçet's disease (BD)-related uveitis and non-infectious uveitis (NIU) unrelated to …

Introduction We aimed to evaluate the efficacy, safety, and immunogenicity profile of
Etanercept (ETA) and Adalimumab (ADA) biosimilars (BIOs) compared to their originators in …

Introduction Since many biological drug patents have expired, biosimilar agents (BIOs) have
been developed; however, there are still some reservations in their use, especially in …

Methods: Patients 18 years old or below treated with reference or biosimilar TNF-alpha
inhibitor for noninfectious uveitis and had a history of active ocular inflammation with at least …

Noninfectious uveitis (NIU) in children and adolescents is a rare but treatable cause of visual
impairment in children. Treatments for pediatric NIU and their side effects, along with the …

3 Manchester Royal Eye Hospital, Manchester University Hospitals NHS Foundation Trust,
Manchester Academic Health Science Centre, Manchester UK 4 Centro Europeo di …

Targeted biological therapies have become a significant component of treating rheumatic
diseases since the introduction of the first tumor necrosis factor (TNF) inhibitor in 1998. The …